CohBar - Model CB4211 - Biotechnology for Nonalcoholic Steatohepatitis (NASH) and Obesity
We believe CB4211 offers a differentiated approach to treating nonalcoholic steatohepatitis (NASH) and obesity. Is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP) that plays a key role in regulating metabolism. Has resulted in significant impacts on NASH and obesity in multiple preclinical models. Has been shown in a clinical study to significantly reduce ALT and AST, key biomarkers of liver damage, as well as glucose levels compared to placebo. Resulted in a trend towards lower body weight compared to placebo in a clinical trial.
-
Most popular related searches
Products Details
CLINICAL DEVELOPMENT
In August 2021, we announced positive topline data from our Phase 1a/1b study of CB4211 under development for NASH and obesity. The Phase 1b portion of trial was a 4 week, multi-center, randomized, double blind, placebo-controlled clinical study in 20 obese subjects with fatty liver disease.
Results: The study met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events. Evaluation of the exploratory pharmacodynamic endpoints from the Phase 1b stage of the study comparing CB4211 to placebo demonstrated robust and significant reductions in key biomarkers of liver damage, ALT and AST, a significant decrease in glucose levels, and a trend towards lower body weight after four weeks of treatment. Both the CB4211 and placebo groups had substantial reductions in liver fat content compared to baseline.
Customer reviews
No reviews were found for CohBar - Model CB4211 - Biotechnology for Nonalcoholic Steatohepatitis (NASH) and Obesity. Be the first to review!